The 22 references in paper A. Skorometz A., A. Timofeeva A., I. Milyukhina V., M. Karpenko N., V. Klimenko M., А. Скоромец А., А. Тимофеева А., В. Клименко М., И. Милюхина В., М. Карпенко Н. (2015) “Уровень интерлейкина -10 в сыворотке крови и цереброспинальной жидкости пациентов с болезнью Паркинсона // The level of Int erleukin-10 in serum and cerebrospinal fluid in patient s with Parkinson’s disease” / spz:neicon:nevro:y:2013:i:5:p:27-30

1
Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. mechanisms underlying inflammation in neurodegeneration. cell. 2010; 19; 140 (6): 918—34.
(check this in PDF content)
2
Lucas S.M., Rothwell N.J., Gibson R.M. The role of inflammation in cNs injury and disease. Br. J. Pharmacol. 2006; 147 (suppl. 1): s232—40.
(check this in PDF content)
3
Mosley R.L., Hutter-Saunders J.A., Stone D.K. inflammation and adaptive immunity in Parkinson’s disease. cold spring harb. Perspect. med. 2012; 2(1): 81—93.
(check this in PDF content)
4
Милюхина И.В., Карпенко М.Н., Тимофеева А.А., Клименко В.М., Скоромец А.А. Роль воспаления в патогенезе болезни Паркинсона. Неврол. журн. 2013; 18(3): 51—5.
(check this in PDF content)
5
Chen C.C., Manning A.M. cytokine. 1996; 8(1): 58—65.
(check this in PDF content)
6
Arimoto T., Choi D. Y., Lu X., Liu M., Nguyen X.V., Zheng N. et al. interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol. aging. 2007; 28 (6): 894—906.
(check this in PDF content)
7
Hoehn M., Jahr M.D. Parkinsonism: onset, progression and mortality. Neurology. 1967; 17(5): 427—42.
(check this in PDF content)
8
Gibb W., Lees A. The relevance of lewy body to the pathogenesis of idiopathic Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry. 1988; 51: 745—52.
(check this in PDF content)
9
Fahn S., Elton R. unified Parkinson’s disease rating scale. recent developments in Parkinson’s disease. mcmillan healthcare inform. 1987; 5: 153—63.
(check this in PDF content)
10
Folstein M.F., Folstein S.E., McHugh P.R. mini-mental status. J. Psychiatr. res. 1975; l2: 189—96.
(check this in PDF content)
11
Manos P.J., Wu R . The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients. int. J. Psychiatry med. 1994; 24 (3):229—44.
(check this in PDF content)
12
Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. acta Psychiatr. scand. 1983; 67: 361—70.
(check this in PDF content)
13
Rentzos M., Nikolaou C., Andreadou E., Paraskevas G.P., Rombos A., Zoga M. et al. circulating interleukin-10 and interleukin-12 in Parkinson’s disease. acta Neurol. scand. 2009; 119: 332—7.
(check this in PDF content)
14
Залялова З.А. Дрожательные фенотипы болезни Паркинсона. Руководство для врачей. В кн.: Иллариошкин С.Н., Левина О.С., ред. По материалам ii Национального конгресса по болезни Паркинсона и расстройствам движений. М.: НЦН РАМН; 2011: 55—9.
(check this in PDF content)
15
Rooden S.M., Heiser W.J., Kok J.N., Verbaan D., van Hilten J.J., Marinus J. The identification of Parkinson’s disease subtypes using cluster analysis: a systematic review. movement disord. 2010; 25(8): 969—78.
(check this in PDF content)
16
Raison C.L., Capuron L., Miller A.H. cytokines sing the blues: inflammation and the pathogenesis of depression. Trends immunol. 2006; 27 (1): 24—31.
(check this in PDF content)
17
Miller A.H., Maletic V., Raison C.L. inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry. 2009; 65 (9): 732—41.
(check this in PDF content)
18
Kubera M., Kenis G., Bosmans E., Zieba A., Dudek D., Nowak G., Maes M. Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Pol. J. Pharmacol. 2000; 52 (3): 237—41.
(check this in PDF content)
19
Huang T., Chien-Te L. T-helper 1/T-helper 2 cytokine imbalance and clinical phenotypes of acute-phase major depression. Psychiatry clin. Neurosci. 2007, 61: 415—20.
(check this in PDF content)
20
Parissis J.T., Adamopoulos S., Rigas A., Kostakis G., Karatzas D., Venetsanou K. et. al. comparison of circulating proinflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression. am. J. cardiol. 2004; 94 (10): 1326—8.
(check this in PDF content)
21
Rothermundt M., Arolt V., Peters M., Gutbrodt H., Fenker J., Kersting A. et al. inflammatory markers in major depression and melancholia. J. affect. disord. 2001; 63 (1—3): 93—102.
(check this in PDF content)
22
Левин О.С. Психические расстройства при болезни Паркинсона и их коррекция. В кн.: Шток В.Н., ред. Экстрапирамидные расстройства. Руководство по диагностике и лечению. М.: Медпресс-информ; 2002: 125—51.
(check this in PDF content)